Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination

Ujueta, Francisco; Azimi, Roshanak; Lozier, Matthew R.; Poppiti, Robert; Ciment, Ari

doi:10.1016/j.ijcha.2021.100869

Cited by 16 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…She was immediately administered maximal doses of vasopressin, phenylephrine, and epinephrine but developed cardiac arrest and expired a few hours later. Lymphohistiocytic myocarditis with sparse eosinophils was detected on autopsy 9 …”

Section: Discussionmentioning

confidence: 98%

“…However, there have been recent reports of myocarditis following adenovirus vector COVID‐19 vaccines as well. 5 , 6 , 7 , 8 , 9 , 10 …”

Section: Discussionmentioning

confidence: 99%

“…Most of the reported cases of post‐vaccination myocarditis are following mRNA COVID‐19 vaccinations and the majority of the patients are young males. However, there have been recent reports of myocarditis following adenovirus vector COVID‐19 vaccines as well 5‐10 …”

Section: Discussionmentioning

confidence: 99%

“…However, there have been recent reports of myocarditis after adenovirus vector vaccines (AstraZeneca and Janssen). 5 , 6 , 7 , 8 , 9 …”

Section: Introductionmentioning

confidence: 99%

“…However, there have been recent reports of myocarditis after adenovirus vector vaccines (AstraZeneca and Janssen). [5][6][7][8][9] Most individuals that develop myopericarditis following COVID-19 vaccination present with various signs and symptoms such as chest pain, tachycardia, palpitation, hypotension, edema, clinical features of decreased cardiac output, shortness of breath, fatigue, fever, nausea, and vomiting. The workup of these patients usually includes testing for inflammatory and cardiac biomarkers, serologic SARS-CoV-2 antibodies level, electrocardiogram (ECG), echocardiogram, and cardiac magnetic resonance imaging (CMR).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report

Hassanzadeh¹,

Sadeghi

Mirdamadi

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

Coronavirus disease‐19 (COVID‐19) vaccines are massively administered globally and some adverse events, such as myocarditis, are being reported. Most of the reported cases of post‐vaccination myocarditis have occurred following mRNA vaccinations. However, there have also been recent reports of myocarditis following adenovirus vector vaccinations. We present a case of a 32‐year‐old female patient who developed myocarditis following the administration of the first dose of the AstraZeneca vaccine. The patient developed inappropriate exertional tachycardia and exertional dyspnea from Day 3 and was diagnosed with myocarditis by subsequent echocardiography about 3 months later. We are unable to confirm a direct association between myocarditis and AstraZeneca vaccination. However, we would like to increase awareness regarding the possibility of developing myocarditis following AstraZeneca vaccination.

show abstract

Section: Discussionmentioning

confidence: 98%

“…However, there have been recent reports of myocarditis following adenovirus vector COVID‐19 vaccines as well. 5 , 6 , 7 , 8 , 9 , 10 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…However, there have been recent reports of myocarditis after adenovirus vector vaccines (AstraZeneca and Janssen). 5 , 6 , 7 , 8 , 9 …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report

Hassanzadeh¹,

Sadeghi

Mirdamadi

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 2021

Ilonze

Guglin

2022

Heart Fail Rev

View full text Add to dashboard Cite

Clinical course and outcomes of myocarditis after COVID-19 vaccination remain variable. We retrospectively collected data on patients > 12 years old from 01/01/2021 to 12/30/2021 who received COVID-19 messenger RNA (mRNA) vaccination and were diagnosed with myocarditis within 60 days of vaccination. Myocarditis cases were based on case definitions by authors. We report on 238 patients of whom most were male (n = 208; 87.1%). The mean age was 27.4 ± 16 (range 12-80) years. Females presented at older ages (41.3 ± 21.5 years) than men 25.7 ± 14 years (p = 0.001). In patients > 20 years of age, the mean duration from vaccination to symptoms was 4.8 days ± 5.5 days, but in < 20, it was 3.0 ± 3.3 days (p = 0.04). Myocarditis occurred most commonly after the Pfizer-BioNTech mRNA vaccine (n = 183; 76.45) and after the second dose (n = 182; 80%). Symptoms started 3.95 ± 4.5 days after vaccination. The commonest symptom was chest pain (n = 221; 93%). Patients were treated with non-steroidal anti-inflammatory drugs (n = 105; 58.3%), colchicine (n = 38; 21.1%), or glucocorticoids (n = 23; 12.7%). About 30% of the patients had left ventricular ejection fraction but more than half recovered the on repeat imaging. Abnormal cardiac MRIs were common; 168 patients (96% of 175 patients that had MRI) had late gadolinium enhancement, while 120 patients (68.5%) had myocardial edema. Heart failure guideline-directed medical therapy use was common (n = 27; 15%). Eleven patients had cardiogenic shock; and 4 patients required mechanical circulatory support. Five patients (1.7%) died; of these, 3 patients had endomyocardial biopsy/autopsy-confirmed myocarditis. Most cases of COVID-19 vaccine myocarditis are mild. Females presented at older ages than men and duration from vaccination to symptoms was longer in patients > 20 years. Cardiogenic shock requiring mechanical circulatory support was seen and mortality was low. Future studies are needed to better evaluate risk factors, and long-term outcomes of COVID-19 mRNA vaccine myocarditis.

show abstract

Fulminant Myocarditis Temporally Associated with COVID-19 Vaccination

Ammirati,

Conti,

Palazzini

et al. 2024

Curr Cardiol Rep

View full text Add to dashboard Cite

Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination

Cited by 16 publications

References 10 publications

Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report

Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report

Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 2021

Fulminant Myocarditis Temporally Associated with COVID-19 Vaccination

Contact Info

Product

Resources

About